Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)
1. Barzolvolimab met primary endpoint but failed to improve EoE symptoms. 2. Favorable safety profile observed for barzolvolimab’s 300 mg dosing. 3. Celldex will not pursue EoE development for barzolvolimab. 4. Ongoing studies include two Phase 3 trials for chronic spontaneous urticaria. 5. Future focus on mast cell targeting therapies for other GI conditions.